|
|
 |
 |
 |
Chapter 3: General Principles: Pharmacodynamics
|
|
|
|
|
|
|
Introduction
Two of the most clinically consequential phenomena in pharmacodynamics arise not from the initial drug-receptor interaction, but adaptive physiological response to sustained drug exposure.
Tolerance, a progressive reduction in a drug effect with repeated administration, requiring dose escalation to maintain the same response, and physical dependence, the physiological state in which drug removal produces a characteristic withdrawal syndrome, are consequences receptor regulation mechanisms.
Opioid tolerance is a leading promoter of dose escalation in chronic pain management. Tolerance is also a contributor to the opioid epidemic, and a key determinant of therapeutic outcomes.
Beta-blocker withdrawal can precipitate myocardial infarction in patients with coronary artery disease.
Abrupt glucocorticoid discontinuation can cause adrenal crisis.
Benzodiazepine withdrawal can produce life-threatening seizures.
In each case, the clinical risk is a direct consequence of receptor regulation mechanisms that are pharmacologically predictable and therefore preventable.1,2
We will consider receptor regulation from its molecular origins, G-protein-coupled receptor kinases phosphorylation and β-arrestin binding through cellular consequences, desensitization, internalization, downregulation, upregulation, to clinical manifestations, tolerance, tachyphylaxis, withdrawal syndromes, physical dependence, with specific clinical examples throughout.
Regulatory Cascade: Desensitization
Desensitization is the rapid, agonist-induced reduction in receptor responsiveness that occurs within seconds to minutes of sustained activation, before any change in receptor number has taken place.
Desensitization is the first and fastest layer of receptor regulation and is mechanistically distinct from the slower processes of internalization and downregulation.
The molecular mechanism of G-protein-coupled receptor desensitization is a two-step process:3,6,7
Step 1: GRK phosphorylation
Agonist binding activates the receptor and simultaneously promotes its recognition by G protein-coupled receptor kinases (GRKs).
GRKs phosphorylate specific serine and threonine residues in the intracellular loops and C-terminal tail of the agonist-occupied receptor.
This phosphorylation event does not itself impair G protein coupling significantly, but it creates high-affinity binding sites for β-arrestin proteins.
The time scale for GRK phosphorylation is rapid, saturating within approximately 20 seconds of agonist exposure at the μ-opioid receptor.6
Step 2: β-Arrestin recruitment
β-Arrestins (β-arrestin-1 and β-arrestin-2, also called arrestin-2 and arrestin-3) bind to GRK-phosphorylated receptors with high affinity.
β-Arrestin binding sterically occludes the intracellular surface of the receptor, physically preventing G protein reassociation.
This is the primary mechanism of homologous desensitisation that is, selective uncoupling of an activated, phosphorylated receptor from its G protein, reaching near-steady state within approximately 2–5 minutes.3,6
Desensitization is homologous when it affects only the receptor that has been activated and phosphorylated by GRK, a self-limiting feedback mechanism.
Heterologous desensitisation occurs when second messenger-dependent kinases (PKA, PKC) phosphorylate and uncouple receptors regardless of whether they have been directly activated, producing broader suppression of signaling across a receptor population.
Desensitization provides a built-in brake on prolonged receptor signaling, preventing sustained overstimulation.
Clinical consequence
Any drug that produces sustained agonist activity at a GPCR will trigger desensitization, reducing its own effectiveness.
Onset of β-agonist tachyphylaxis during continuous nebulization and the short-lived nature of short-acting opioid analgesia compared with intermittent dosing are both manifestations of desensitisation.1,2
Internalization and Receptor Trafficking
Following β-arrestin binding, the receptor-β-arrestin complex engages the clathrin-coated pit endocytic machinery.
β-Arrestins serve as adaptors between the phosphorylated receptor and the endocytic proteins clathrin and AP-2, directing receptor-β-arrestin complexes into coated vesicles that are internalized by dynamin-mediated membrane scission.3,6
Once internalized into early endosomes, the receptor follows one of two paths.
Recycling
The receptor dissociates from its ligand and β-arrestin in the acidic endosomal environment, is dephosphorylated by endosomal phosphatases, and is returned to the plasma membrane in a resensitized (fully functional) state.
This pathway predominates after brief agonist exposure and represents a restorative mechanism that, if operative, limits the development of prolonged tolerance.
Degradation (downregulation)
The receptor is trafficked from early endosomes to late endosomes and ultimately to lysosomes, where it is proteolytically degraded.
This process reduces total receptor protein and receptor number, true downregulation,and requires new receptor synthesis for recovery, a process taking hours to days.
Sustained or high-efficacy agonist exposure favours the degradation pathway over the recycling pathway.3,5,6
A pharmacologically important nuance emerges from this trafficking distinction:
Not all opioid agonists drive internalization equally, and this influences their tolerance profiles.
Highly efficacious agonists at the μ-opioid receptor (DAMGO, etorphine, fentanyl) promote:
Efficient GRK phosphorylation,
Robust β-arrestin recruitment, and
Rapid receptor internalization followed predominantly by recycling and resensitization.
Morphine, by contrast, is a relatively poor inducer of GRK phosphorylation and β-arrestin recruitment at therapeutic concentrations.
Morphine desensitizes receptors without efficiently internalizing them.3,6
The internalized-then-recycled receptor recovers function
The surface-retained, morphine-desensitized receptor does not recover as efficiently.
This process may be one mechanistic contributor to morphine's pronounced clinical tolerance profile.
|
|
|
|
|
|
|
|